| Nov 21 |
Health Canada Authorizes CARVYKTI® (ciltacabtagene autoleucel) for Patients with Relapsed or Refractory Multiple Myeloma Who Have Received One to Three Prior Lines of Therapy
|
| Nov 20 |
Update: Market Chatter: Johnson & Johnson, Merck Cut Jobs in China
|
| Nov 19 |
Large caps in trouble? Key takeaways from Tommy Tuberville's latest trades
|
| Nov 19 |
Johnson & Johnson: Policy Uncertainty Elevated, But Shares Remain Inexpensive
|
| Nov 19 |
Johnson & Johnson to showcase strength of its broad hematology portfolio and pipeline at the 2024 American Society of Hematology Annual Meeting
|
| Nov 19 |
J&J pill clears skin in two late-stage psoriasis studies
|
| Nov 19 |
Johnson & Johnson reports topline outcomes from trial of icotrokinra for psoriasis
|
| Nov 18 |
J&J unveils positive phase 3 results for icotrokinra for plaque psoriasis
|
| Nov 18 |
Icotrokinra delivered an industry-leading combination of significant skin clearance with demonstrated tolerability in a once daily pill in Phase 3 topline results
|
| Nov 18 |
Johnson & Johnson (JNJ) Management presents at Stifel 2024 Healthcare Conference (Transcript)
|
